TABLE 3.
Response of patients treated with venetoclax and decitabine or azacitidine.
| Response | ||||
|---|---|---|---|---|
| Response Category |
All patients (N = 66)A |
Decitabine‐venetoclax (N = 43)B |
Azacitidine‐venetoclax (N = 23)C |
Significance |
| Complete remission (CR) | 3 (4.5) | 2 (4.7) | 1 (4.3) | p > 0.999 |
| Complete remission with incomplete hematologic recovery (CRi) | 18 (27.3) | 14 (32.6) | 4 (17.4) | p = 0.251 |
| Complete remission with partial hematologic recovery (CRh) | 5 (7.8) | 3 (7.0) | 2 (8.7) | p > 0.999 |
| Composite complete remission (CR + CRi + CRh) | 26 (39.4) | 19 (44.2) | 7 (30.4) | p = 0.304 |
| Composite complete remission by ELN 2017 cytogenetic risk category—no. (%)D | ||||
| FavorableE | 5 (41.2) | 3 (42.9) | 2 (40.0) | p > 0.999 |
| IntermediateF | 5 (38.5) | 4 (50.0) | 1 (20.0) | p = 0.301 |
| AdverseG | 16 (44.4) | 12 (52.2) | 4 (30.7) | p = 0.301 |
A: Sixty‐six of 74 patients were evaluable for response.
B: Forty‐three of 48 evaluable patients in the decitabine cohort were evaluable for response.
C: Twenty‐three of 26 evaluable patients in the azacitidine cohort were evaluable for response.
D: Forty‐six of 48 patients in the decitabine cohort and 25 of 26 in the azacitidine cohort had ELN 2017 risk known at diagnosis.
E: Seven of nine favorable‐risk patients in the decitabine cohort were evaluable for response.
F: Eight of nine intermediate‐risk patients in the decitabine cohort and five of six intermediate‐risk patients in the azacitidine cohort were evaluable for response.
G: Twenty‐three of 26 adverse‐risk patients in the decitabine cohort and 13 of 14 adverse‐risk patients in the azacitidine cohort were evaluable for response.